

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

November 2010

Vol. 38, No. 11

CONTENTS

SHORT COMMUNICATIONS

Bilirubin Glucuronidation Revisited: Proper Assay Conditions to Estimate Enzyme Kinetics with Recombinant UGT1A1. *Jin Zhou, Timothy S. Tracy, and Rory P. Remmel* **1907**

A 96-Well Plate Assay for CYP4503A Induction Using Cryopreserved Human Hepatocytes. *Naomi Kamiguchi, Eiji Aoyama, Teruaki Okuda, and Toshiya Moriwaki* **1912**

Reduction of *N*-Hydroxy-sulfonamides, Including *N*-Hydroxy-valdecoxib, by the Molybdenum-Containing Enzyme mARC. *Antje Havemeyer, Sanja Grünwald, Bettina Wahl, Florian Bittner, Ralf Mendel, Péter Erdélyi, János Fischer, and Bernd Clement* **1917**

Effect of Regular Organic Solvents on Cytochrome P450-Mediated Metabolic Activities in Rat Liver Microsomes. *Dan Li, Yonglong Han, Xiangli Meng, Xipeng Sun, Qi Yu, Yan Li, Lili Wan, Yan Huo, and Cheng Guo* **1922**

ARTICLES

[S] Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution. *Brian J. Kirby and Jashvant D. Unadkat* **1926**

[S] Detection of Phenolic Metabolites of Styrene in Mouse Liver and Lung Microsomal Incubations. *Shuijie Shen, Fan Zhang, Lingbo Gao, Su Zeng, and Jiang Zheng* **1934**

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation

by Dipeptidyl Peptidase IV and Neutral Endopeptidase. *Monika Malm-Erjefält, Inga Björnsdóttir, Jan Vanggaard, Hans Helleberg, Uffe Larsen, Berend Oosterhuis, Jan Jaap van Lier, Milan Zdravkovic, and Anette K. Olsen* **1944**

[S] Effect of Hepatitis C Virus Infection on the mRNA Expression of Drug Transporters and Cytochrome P450 Enzymes in Chimeric Mice with Humanized Liver. *Ryota Kikuchi, Matthew McCown, Pamela Olson, Chise Tatenno, Yoshio Morikawa, Yumiko Katoh, David L. Bourdet, Mario Monshouwer, and Adrian J. Fretland* . . . **1954**

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors. *Tarek Mekhail, Eric Masson, Bruce S. Fischer, Jiachang Gong, Ramaswamy Iyer, Jinping Gan, Janice Pursley, Daniel Patricia, Daphne Williams, and Ram Ganapathi* . . . **1962**

Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys. *Haruka Nishimuta, Kimihiko Sato, Yasuyuki Mizuki, Masashi Yabuki, and Setsuko Komuro* **1967**

[S] CYP2C8 Exists as a Dimer in Natural Membranes. *Gang Hu, Eric F. Johnson, and Byron Kemper* . **1976**

[S] Metabolism, Pharmacokinetics, and Excretion of the 5-Hydroxytryptamine_{1B} Receptor Antagonist Elzasonan in Humans. *Amin Kamel, R. Scott Obach, Kevin Colizza, Weiwei Wang, Thomas N. O'Connell, Richard V. Coelho Jr., Ryan M. Kelley, and Klaas Schildknegt* **1984**

ATP-Binding Cassette B1 Transports Seliciclib (*R*-Roscovitine), a Cyclin-Dependent Kinase Inhib-

Continued on next page

- itor. *Zsuzsanna Rajnai, Dóra Méhn, Erzsébet Beéry, Alper Okyar, Márton Jani, Gábor K. Tóth, Ferenc Füllöp, Francis Lévi, and Peter Krajcsi* . **2000**
- Metabolism of 1'- and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7. *Kyung-Ah Seo, Soo Kyung Bae, Young-Kil Choi, Chang Soo Choi, Kwang-Hyeon Liu, and Jae-Gook Shin* **2007**
- Isolation and Identification of Phase 1 Metabolites of Curcumol in Rats. *Yan Lou, Hui Zhang, Hao He, Kaifeng Peng, Ning Kang, Xingchuan Wei, Xuegai Li, Lixia Chen, Xinsheng Yao, and Feng Qiu* **2014**
- Metabolism, Excretion, and Pharmacokinetics of [¹⁴C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans. *Adam D. Shilling, Frank M. Nedza, Thomas Emm, Sharon Diamond, Edward McKeever, Naresh Punwani, William Williams, Argyrios Arvanitis, Laurine G. Galya, Mei Li, Stacey Shepard, James Rodgers, Tai-Yuen Yue, and Swamy Yeleswaram* **2023**
- ☐ Drug Metabolism and Pharmacokinetics of 4-Substituted Methoxybenzoyl-aryl-thiazoles. *Chien-Ming Li, Yan Lu, Ramesh Narayanan, Duane D. Miller, and James T. Dalton* **2032**
- ☐ Profiling of the Compounds Absorbed in Human Plasma and Urine after Oral Administration of a Traditional Japanese (Kampo) Medicine, Daikenchuto. *Jun Iwabu, Junko Watanabe, Kazuhiro Hirakura, Yoshinori Ozaki, and Kazuhiro Hanazaki* **2040**
- Metabolism and Disposition of [¹⁴C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans. *Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong, and Steven Zhang* **2049**
- Human Heme Oxygenase-1 Efficiently Catabolizes Heme in the Absence of Biliverdin Reductase. *James R. Reed, Warren J. Huber III, and Wayne L. Backes* **2060**
- Identification of Two Novel Metabolites of SCH 486757, a Nociceptin/Orphanin FQ Peptide Receptor Agonist, in Humans. *Natalia A. Penner, Ginny Ho, Ana Bercovici, Swapan K. Chowdhury, and Kevin B. Alton* **2067**
- ☐ Effects of a Commonly Occurring Genetic Polymorphism of Human CYP3A4 (I118V) on the Metabolism of Anandamide. *Matthew Pratt-Hyatt, Haoming Zhang, Natasha T. Snider, and Paul F. Hollenberg* **2075**
- Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties. *Rishi R. Gupta, Eric M. Gifford, Ted Liston, Chris L. Waller, Moses Hoffman, Barry A. Bunin, and Sean Ekins* **2083**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The chemical space of the HLM training dataset (red circles) and the test set of 2300 compounds (blue circles). See the article by Gupta et al. on page 2083 of this issue.